Search Results - "Vanderveen, Laurie"

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models by Charych, Deborah H, Hoch, Ute, Langowski, John L, Lee, Steve R, Addepalli, Murali K, Kirk, Peter B, Sheng, Dawei, Liu, Xiaofeng, Sims, Paul W, VanderVeen, Laurie A, Ali, Cherie F, Chang, Thomas K, Konakova, Marina, Pena, Rhoneil L, Kanhere, Rupesh S, Kirksey, Yolanda M, Ji, Chunmei, Wang, Yujun, Huang, Jicai, Sweeney, Theresa D, Kantak, Seema S, Doberstein, Stephen K

“…Aldesleukin, recombinant human IL2, is an effective immunotherapy for metastatic melanoma and renal cancer, with durable responses in approximately 10% of…”
Get full text

Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People with HIV-1 Suppressed by Antiretroviral Therapy by Selzer, Lisa, VanderVeen, Laurie A, Parvangada, Aiyappa, Martin, Ross, Collins, Sean E, Mehrotra, Megha, Callebaut, Christian

“…HIV envelope (env) diversity may result in resistance to broadly neutralizing antibodies (bNAbs). Assessment of genotypic or phenotypic susceptibility to…”
Get full text

Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model by Bekerman, Elena, Yant, Stephen R, VanderVeen, Laurie, Hansen, Derek, Lu, Bing, Rowe, William, Wang, Kelly, Callebaut, Christian

“…Long-acting antiretroviral agents for preexposure prophylaxis (PrEP) represent a promising new alternative to daily oral regimens for HIV prevention…”
Get full text

Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data by D'Antoni, Michelle L, Andreatta, Kristen, Chang, Silvia, Cox, Stephanie, Hindman, Jason T, Avihingsanon Anchalee, Martin, Hal, VanderVeen, Laurie A, Callebaut, Christian

“…Background:In the phase 3 ALLIANCE study, both bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and dolutegravir plus emtricitabine/tenofovir…”
Get full text

HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection by VanderVeen, Laurie A, Selzer, Lisa, Moldt, Brian, Parvangada, Aiyappa, Li, Jiani, Ananworanich, Jintanat, Crowell, Trevor A, Eron, Joseph J, Daar, Eric S, Haubrich, Richard, Geleziunas, Romas, Cyktor, Joshua, Mellors, John W, Callebaut, Christian

“…We studied the relationship between viral diversity and susceptibility to broadly neutralizing antibodies (bNAbs) in longitudinal plasma and peripheral blood…”
Get full text

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial by Gupta, Samir K, Berhe, Mezgebe, Crofoot, Gordon, Benson, Paul, Ramgopal, Moti, Sims, James, McDonald, Cheryl, Ruane, Peter, Sanchez, William E, Scribner, Anita, Liu, Shan-Yu, VanderVeen, Laurie A, Dvory-Sobol, Hadas, Rhee, Martin S, Baeten, Jared M, Koenig, Ellen

“…Antiretroviral agents with novel mechanisms and dosing intervals could expand treatment options for people with HIV. Lenacapavir, an inhibitor of capsid…”
Get full text

Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study by Eron, Joseph J, Little, Susan J, Crofoot, Gordon, Cook, Paul, Ruane, Peter J, Jayaweera, Dushyantha, VanderVeen, Laurie A, DeJesus, Edwin, Zheng, Yanan, Mills, Anthony, Huang, Hailin, Waldman, Sarah E, Ramgopal, Moti, Gorgos, Linda, Collins, Sean E, Baeten, Jared M, Caskey, Marina

“…Long-acting treatment for HIV has potential to improve adherence, provide durable viral suppression, and have long-term individual and public health benefits…”
Get full text

NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases by Dixit, Neha, Fanton, Christie, Langowski, John L., Kirksey, Yolanda, Kirk, Peter, Chang, Thomas, Cetz, Janet, Dixit, Vidula, Kim, Grace, Kuo, Peiwen, Maiti, Mekhala, Tang, Yinyan, VanderVeen, Laurie A., Zhang, Ping, Lee, Myong, Ritz, Jerome, Kamihara, Yusuke, Ji, Chunmei, Rubas, Werner, Sweeney, Theresa D., Doberstein, Stephen K., Zalevsky, Jonathan

“…Impaired interleukin-2 (IL-2) production and regulatory T-cell dysfunction have been implicated as immunological mechanisms central to the pathogenesis of…”
Get full text

Induction of Frameshift and Base Pair Substitution Mutations by the Major DNA Adduct of the Endogenous Carcinogen Malondialdehyde by VanderVeen, Laurie A., Hashim, Muhammed F., Shyr, Yu, Marnett, Lawrence J.

“…Instability of repetitive sequences is a hallmark of human cancer, and its enhancement has been linked to oxidative stress. Malondialdehyde is an endogenous…”
Get full text

In vivo and in vitro Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic Development by Lee, Alex S, Tiwari, Suchi, Bishop, Isabel, Matossian, Vartan, Romaneschi, Nicole, Miyazaki, Takahiro, VanderVeen, Laurie, Zalevsky, Jonathan, DeFea, Kathryn, Cahill, Catherine M, Walwyn, Wendy M

“…Mu opioid receptor (MOPr) agonists are well-known and frequently used clinical analgesics but are also rewarding due to their highly addictive and often…”
Get full text

Formation of DNA−Protein Cross-Links Between γ-Hydroxypropanodeoxyguanosine and EcoRI by VanderVeen, Laurie A, Harris, Thomas M, Jen-Jacobson, Linda, Marnett, Lawrence J

“…The toxicity of acrolein, an α,β-unsaturated aldehyde produced during lipid peroxidation, is attributable to its high reactivity toward DNA and cellular…”
Get full text

Differential DNA Recognition and Cleavage by EcoRI Dependent on the Dynamic Equilibrium between the Two Forms of the Malondialdehyde−Deoxyguanosine Adduct by VanderVeen, Laurie A, Druckova, Alexandra, Riggins, James N, Sorrells, Jennifer L, Guengerich, F. Peter, Marnett, Lawrence J

“…DNA damage may alter the outcome of protein−nucleic acid interactions. The malondialdehyde−deoxyguanosine adduct,…”
Get full text

Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir by Margot, Nicolas A, Naik, Vidula, VanderVeen, Laurie, Anoshchenko, Olena, Singh, Renu, Dvory-Sobol, Hadas, Rhee, Martin S, Callebaut, Christian

“…Lenacapavir (LEN) is a first-in-class inhibitor of human immunodeficiency virus type 1 (HIV-1) capsid function in clinical development for the treatment of…”
Get full text

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study by Margot, Nicolas, Vanderveen, Laurie, Naik, Vidula, Ram, Renee, Parvangada, PC, Martin, Ross, Rhee, Martin, Callebaut, Christian

“…Abstract Background Lenacapavir in vitro resistance selections identified seven mutations in HIV-1 capsid protein (CA) associated with reduced susceptibility…”
Get full text

Evaluation of the Mutagenic Potential of the Principal DNA Adduct of Acrolein by VanderVeen, Laurie A., Hashim, Muhammed F., Nechev, Lubomir V., Harris, Thomas M., Harris, Constance M., Marnett, Lawrence J.

“…Acrolein is produced extensively in the environment by incomplete combustion of organic materials, and it arises endogenously in humans as a metabolic…”
Get full text

HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data by D’Antoni, Michelle L., Andreatta, Kristen, Chang, Silvia, Cox, Stephanie, Hindman, Jason T., Avihingsanon, Anchalee, Martin, Hal, VanderVeen, Laurie A., Callebaut, Christian

“…Background: In the Phase 3 ALLIANCE study, both bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and dolutegravir plus emtricitabine/tenofovir…”
Get full text

Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data: Erratum

Get full text

P124 - Molecular determinants of the inherently slow entry of NKTR-181 into the brain by Odinecs, Aleksandrs, Rubas, Werner, Lee, Myong, Vanderveen, Laurie, Eldon, Michael, Hoch, Ute, Zalevsky, Jonathan, Doberstein, Stephen

Get full text

Abstract 3265: NKTR-255, a polymer-conjugated IL-15 enhances anti-tumor NK cell responses and synergizes with monoclonal antibodies to provide long-term survival in human lymphoma model by Miyazaki, Takahiro, Kivimäe, Saul, Pena, Rhoneil, Kuo, Peiwen, Hennessy, Marlene, Addepalli, Murali, Dixit, Neha, Nieves, Wildaliz, Sheibani, Sara, Maiti, Mekhala, VanderVeen, Laurie, Wilczek, Joanna, Madakamutil, Loui, Zalevsky, Jonathan

“…Abstract Background: IL-15 is a cytokine that activates and provides survival benefit to NK cells. Exploiting the therapeutic value of native IL-15 has been…”
Get full text

Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents by Kopruszinski, Caroline M., Swiokla, Juliana, Lee, Yeon Sun, Navratilova, Edita, VanderVeen, Laurie, Yang, Miao, Liu, Yi, Miyazaki, Takahiro, Schmidt, William K., Zalevsky, Jonathan, Porreca, Frank

“…Objective Pharmacological evaluation of the mu-opioid receptor (MOR) agonist properties of NKTR-181 in rodent models. Methods Graded noxious stimulus…”
Get full text